Figure 4.
![Transient inhibition of RUNX1 proteolytic degradation during megakaryocytic differentiation of RUNX1-FPD iPSCs. (A) In vitro iPSC megakaryocyte differentiation with drug treatment. (B) Representative flow diagrams of iPSC-derived megakaryocyte progenitors (CD41a+/CD45−). (C) Relative fold change of megakaryocyte progenitors generated from in vitro iPSC differentiation (FPD-iPSCs [n = 3]; isogenic and wild-type N-2.12 control cells [n = 2]). (D) Scored iPSC-derived megakaryocyte colonies after 14 days of a CFU assay. Error bars show standard deviation. *P < .05, using a 2-tailed Student t test assuming unequal variance.](https://ash.silverchair-cdn.com/ash/content_public/journal/bloodadvances/5/3/10.1182_bloodadvances.2020002709/2/advancesadv2020002709f4.png?Expires=1735822722&Signature=oZLrPtKAoM1~oqfQu37x9tjZkI9ZYFs5eY5c7x1YNhqQd4yoLgiUZuerbGYM3~VtD60JLBE2tA1Tqg~xczKRZRCKwyE0-MZw-ZIhaIqF003IDSbZHvtcYK9O66LyyVVE4wXocspeQyQ9UeMj7vPOPw8QmM3cQ0yidBI05~SGxR9UldXkGnLxeO6Ge3TgbeskNiA1baXMqSDnvdrXaTd0gOHizVye0LQOnYQeN9Sk6PEOjttVvN9PgZ76uUKCqOxIbpAt2pLGHTdwPb0UkPVby7MOUZxoZLonKN6hF~U8CdyfFP8C0XxChoRNtIva2QY~lD5aVvbj2-YeX4n4KoOh5g__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Transient inhibition of RUNX1 proteolytic degradation during megakaryocytic differentiation of RUNX1-FPD iPSCs. (A) In vitro iPSC megakaryocyte differentiation with drug treatment. (B) Representative flow diagrams of iPSC-derived megakaryocyte progenitors (CD41a+/CD45−). (C) Relative fold change of megakaryocyte progenitors generated from in vitro iPSC differentiation (FPD-iPSCs [n = 3]; isogenic and wild-type N-2.12 control cells [n = 2]). (D) Scored iPSC-derived megakaryocyte colonies after 14 days of a CFU assay. Error bars show standard deviation. *P < .05, using a 2-tailed Student t test assuming unequal variance.